Author:
Karlberg M.,Kizhedath A.,Glassey J.
Publisher
Springer International Publishing
Reference69 articles.
1. Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F. & Motlagh, S. Predicting antibody developability profiles through early stage discovery screening. Mabs, 2020. Taylor & Francis, 1743053.
2. Kizhedath, A., Karlberg, M. & Glassey, J. 2019. Cross-interaction chromatography-based Qsar model for early-stage screening to facilitate enhanced developability of monoclonal antibody therapeutics. Biotechnology Journal, 14, 1800696.
3. Obrezanova, O., Arnell, A., de la Cuesta, R. G., Berthelot, M. E., Gallagher, T. R. A., Zurdo, J. & Stallwood, Y. 2015. Aggregation risk prediction for antibodies and its application to biotherapeutic development. mAbs, 7, 352–363.
4. Zurdo, J., Arnell, A., Obrezanova, O., Smith, N., de la Cuesta, R. G., Gallagher, T. R. A., Michael, R., Stallwood, Y., Ekblad, C., Abrahmsen, L. & Hoiden-Guthenberg, I. 2015. Early Implementation of QbD in Biopharmaceutical Development: A Practical Example. Biomed Research International.
5. Rathore, A. S., Singh, S. K., Kumar, J. & Kapoor, G. 2018. Implementation of QbD for Manufacturing of Biologics—Has It Met the Expectations? Biopharmaceutical Processing. Elsevier.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献